Anti-SARS-CoV-2 IgG profile of protein subunit, adenovector and mRNA vaccines

Sebastian Reinig, Kou-Chin, Chia-Chun Wu, Sheng-Yu Huang, Jau-Song Yu, Shin-ru Shih

Abstract

Different vaccine platforms were developed in 2019 and 2020 to provide immunization for protection against the SARS-CoV-2-caused disease COVID-19. The majority of vaccinated individuals will develop antibodies against SARS-CoV-2. The isotype (subclass) and Fc-glycosylation of IgG antibodies determine their affinity for secondary effector functions. For protein subunit vaccines in COVID-19, the IgG profile of the subclass and glycosylation are unknown. Therefore, we measured the IgG subclass and N-297 Fc glycosylation by ELISA and LC-MS/MS of anti-spike IgG from individuals vaccinated with the Taiwanese protein subunit vaccine Medigen, the mRNA vaccines (BNT, Moderna), and the adenovector Astrazeneca. Samples were taken after the first and second doses. For all vaccine types, the main IgG response was dominated by IgG1 and IgG3 as subclasses. For glycosylation, mRNA vaccines presented with an afucosylation after the first dose and a constant significant higher galactosylation and sialylation than non-mRNA vaccines.

Introduction

The COVID-19 pandemic epidemic in 2019 with SARS-CoV-2 as the primary causal agent has sped up the development of numerous coronavirus vaccines (1). The majority of vaccinated individuals will develop neutralizing antibodies against SARS-CoV-2 (2). Studies have revealed that immunizations offer comparable protection against infection or serious disease as natural infection (3). Anti-SARS-CoV-2 antibody function cannot be fully explained by neutralizing antibodies alone. For instance, substantially lower antibody titers are needed in vaccines to provide the same level of protection as natural infection (4). Immunoglobulin (IgG), the most prevalent antibody in the blood, can activate a variety of secondary effector processes, such as complement activation, macrophagemediated antibody dependent cellular phagocytosis (ADCP), and antibody-dependent cellular cytotoxicity (ADCC) (5). The Fc-domain's structure and affinity for Fc-receptors affect how these secondary activities are activated. The IgG subclass and the conserved n-297 glycosylation site of the Fc-domain determine the structure of the Fc-domain (6). A proinflammatory pattern with higher IgG3 levels and non-fucosylated IgG levels is present in severe COVID-19 disease and may contribute to the progression of the condition. (7–9). According to one study, protein subunit vaccinations induce significant production of fucosylated non-inflammatory antibodies (7). The IgG profile of protein subunit vaccinations in COVID-19 is mostly unknown in people. Our study is the first to examine the IgG profile of the Taiwan-made Medigen protein subunit vaccination (10). We compared the distribution of

anti-spike IgG subclasses, IgG glycosylation, and Medigen adenovector vaccine recipients with Moderna mRNA vaccine recipients. In fact, we were able to confirm that, in contrast to severe COVID-19 disease or mRNA vaccination, no temporary afucosylation took place in Medigen vaccinated individuals. In addition, we discovered a distinctive IgG glycosylation pattern in mRNA vaccine recipients compared to non-mRNA vaccine recipients, with mRNA vaccine recipients having higher levels of galactosylated and sialylated anti-spike IgG.

Results

Anti-spike IgG subclass distribution is IgG1/3 dominated and is similar among different vaccines

All samples came from 41 Taiwanese people who had not been exposed to the disease before receiving the immunization. The participants received vaccine doses from protein subunit vaccine Medigen (MVC-COV1901), adenovector vaccine Astrazeneca (ChAdOx1-S), and both mRNA vaccines Moderna (mRNA-1273) and, BNT (BNT162b2). The only antigen used in all vaccinations is the spike glycoprotein (S) of the SARS-CoV-2 coronavirus. The estimated IgG NT titer increased from the 1st to 2nd dose and was significant higher in the mRNA vaccines in comparison to non-mRNA vaccines (**Figure 1**). The main IgG subclass during the first and second dose against the spike glycoprotein is in all vaccine groups IgG1 and IgG3 in comparison to the signal for pre-vaccination (**Figure 2 A, C**). Anti-S IgG2 and IgG4 are or only slightly elevated before pre-vaccination level (**Figure 2 B, D**). Elevated anti-S IgG4 level are observed after the second vaccination in accordance to other studies in Moderna vaccinated individuals (**Figure 2 D**). However, this was not statistical significant different from other vaccines. Subtle, but significant differences could be found between Medigen and BNT vaccinated with higher anti-S IgG4 level in BNT vaccinated individuals. There were no significant differences in the IgG between the first and second dose of each vaccine (**Figure 2 E-H**).

Anti spike IgG glycosylation showed distinct patterns between mRNA and non-mRNA vaccinated individuals.

IgG1 glycosylation was measured by LC-MS/MS of anti-S IgG1. Here major differences could be identified between mRNA vaccinated (Moderna, BNT) and non-mRNA (Astrazeneca and Medigen). Galactosylation and sialylation were significant higher in mRNA vaccinated (**Figure 3 B,C**). There was also a significant lower sialylation level in Astrazeneca vaccinated in comparison to Medigen vaccinated (**Figure 3 C**). Fucosylation was lower in mRNA vaccinated, but there was no significant difference between Medigen and mRNA vaccinated (**Figure 3 A**). The fucosylation increased from the

first to second dose in mRNA vaccinated (only significant in Moderna vaccinated, **Figure 3 F1**). For galactosylation and sialylation, the pattern is stable among the majority of individuals from the first to second vaccination (**Figure 3 E-G**).

Discussion

This is the initial investigation of the IgG profile of COVID-19 protein subunit vaccines. Similar to other adenovector and mRNA vaccines, the IgG subclass distribution of Medigen was dominated by IgG1/3. This is consistent with previous research on the COVID-19 vaccination as well as subunit protein vaccines against other viruses like hepatitis B (11,12). Recent studies found an increase in anti-S IgG4 after the second or third dose of mRNA vaccines (12,13). After the second dose, we noticed a slight increase in anti-S IgG4, although it was not yet statistically significant. Since it takes 50–150 days after the initial injection for the anti-S IgG4 level to rise in mRNA vaccines, the observation period in our current data may be too short. In hepatitis B protein subunit vaccinations, an escalating level of antigen-specific IgG4 is also seen over time (14). Inclusion of samples at later time points especially after the 3. dose will elucidate if there is also a rise in anti-spike IgG4 after prolonged time.

The most significant findings between the vaccine groups were found in the n-glycosylation level of IgG1 as the main subclass. In agreement to prior studies mRNA vaccines showed lower levels of anti-S IgG1 fucosylation that increase over time and this is in agreement with prior studies (12,15). Medigen and Astrazeneca vaccine recipients did not show early afucosylation and maintained a high anti-S IgG1 fucosylation level in the first and second doses. Since the afucosylation was strongest either in the mRNA vaccinated or infection shortly after seroconversion 7-8 days after vaccination, it cannot be excluded in our study that some afucosylation occurs earlier since all our samples were taken at least 14 days after the injection. In prior studies, it was claimed that soluble antigens like those present in protein subunit vaccines would induce fucosylated antigenic IgG in comparison to situations in which the antigen is membrane-bound (7,16). This is supported by our findings on Medigen IgG glycosylation, while Astrazeneca vaccinations exhibited the greatest levels of fucosylation of any vaccine groups. As a genetic vaccination, AstraZeneca should cause the appearance of the spike protein by transfecting the membrane with the body's own cells. However, because the Astrazeneca vaccine's spike protein contains the furin cleavage site and has the potential to cleave the S1 subunit. This make it possible that a significant portion of the spike protein is a soluble antigen (17,18). Additionally, it was possible to see vaccine-induced free spike protein in blood plasma together with mRNA (19). For a better understanding of the immunization mechanisms in genetic vaccines, further investigations are needed to ascertain the quantity of spike protein that is membrane bound and is free soluble in the blood between the different genetic vaccines. Non-

fucosylated IgG have a larger affinity for the FcγIIIa receptor, which can increase the activation of NK cells and the release of cytokines by spike-protein IgG complexes in macrophages. Low IgG fucosylation can be harmful for COVID-19 and Dengue, but it can be helpful for HIV and malaria infections (16). An initial vaccination with either the subunit protein vaccine or the adenovector vaccine can be used, depending on whether or not high levels of transiently fucosylated IgG are needed. This is because transient fucosylation can be inhibited by preceding immunization with a non-mRNA vaccine (15).

There was a significant trend between non-mRNA and mRNA vaccines for IgG glycosylation, with larger galactosylation and sialylation in mRNA vaccinated individuals. This is consistent with a previous study that found decreased galactosylation and sialylation in Astranzeneca vaccine recipients than in mRNA vaccine recipients (12). Sialylation can promote the expression of inhibitory FcγIIb receptors, while galactosylation should increase the affinity of IgG to the complement system and NK cells (20). The overall impact of these changes may be determined by conducting more functional investigations specifically on PBMCs.

The spike glycoprotein is the only antigen used in all of the vaccinations used in the study. This study offers a novel perspective on the impact of several vaccination platforms on the IgG profile. Additionally, because all of the samples used in this investigation were collected before to Taiwan's first significant COVID-19 outbreak in April 2022 (21), a significant influence from earlier SARS-CoV-2 infection memory may be ruled out. This situation is also unusual since when the mass vaccination program began, the virus had already infected a sizable fraction of the population in most parts of the world (22). There is a considerable chance that previously infected people were included in research on the IgG profile of vaccine recipients since many asymptomatic and mildly infected people might not have been screened or have not developed antibodies against SARS-CoV-2 to confirm a past infection. Therefore this represent a unique study comparing four different vaccine platforms in immune naive individuals with the same antigen.

Methods

Sample collection

Serum and Plasma samples were collected from 41 COVID-19 vaccinated individuals at the Chang Gung University or the Chang Gung Memorial hospital between 14 and 157 days after the injection (median: 27 days). The sample collection period was from June 9th 2021 to January 25th 2022. For the pre-vaccine serum as baseline serum was collected from 10 individuals before vaccination. The age of the from the donors ranged from 21 to 60 years (median: 33 years). 73.75% of the donors were

female. The samples were collected as per protocol SDP-003, Human Biological Specimens Collection, data September 22, 2017 and qualifications of the principal investigator (Robert Pyrtle, M.D.) were reviewed and approved by the Di- agnostics Investigational Review Board (Cummaquid, MA, USA).

IgG NT titer determination

For Each serum sample the NT titer was estimated by MeDiPro SARS-CoV-2 antibody ELISA according to the manufacturer's instructions and calculated according to following study (2).

IgG subclass ELISA

To estimate the composition of Spike protein S1 binding IgG subclasses in the serum, Spike protein was immobilized at a concentration of 2 mg/ml per well using PBS conjugate on the plate overnight. A blocking solution consisting of 5% Bovine serum albumin (BSA) in PBST. All samples were diluted 1:10 with 2.5% BSA in PBST under the same condition. The following mouse anti-human IgG secondary antibodies were utilized: IgG1 at a dilution of 1:2000 (Southern Biotech), IgG3 at a dilution of 1:500 (Southern Biotech), IgG2 at a dilution of 1:500 (Southern Biotech), and IgG4 at a dilution of 1:500 (Southern Biotech). To determine the fold change for IgG subclass the baseline for each subclass was determined by the mean signal of pre-vaccine sera of seronegative individuals.

Anti-spike IgG purification

BcMagTM Tosyl Activated Magnetic Beads (bioclone) were utilized to purify antigen-specific IgG (Spike protein) from serum. For coupling the Spike protein, 100 μg of Spike protein (Sino Biological) was bound to 30 mg of Tosyl magnetic beads. For each sample the beads were then divided equally, with coupling beads containing 2.5 μg of spike protein used for the serum. Elution of antibodies was done by 0.1% Trifluoroacetic acid (TFA). The spike protein-specific IgGs obtained were subsequently analyzed using mass spectrometry.

Preparation for LC-MS/MS

100 mM Tris-HCl was added to 5mg of each anti-spike IgG sample. The samples were reduced with 5 mM TCEP (Sigma) for 30 min at 60 °C and alkylated with 10 mM iodoacetamide (Sigma) in the dark for 35 min at 37 °C. Samples were then digested with trypsin 0.2 mg/ml in 0.1% FA/10% ACN for 16 hours at 37°C. Samples were acidified with 0.5% FA and 0.2% TFA, and each sample was desalted with C18 dissolved in 50 ul (50% ACN/DDW). Taking 5 ml into the insert and Speed Vac, it was dissolving by 6 ml (0.1% FA).

Accurate inclusion mass screening (AIMS)

The tryptic peptide samples were reconstituted in High-performance liquid chromatography (HPLC) buffer A (0.1% formic acid), loaded across a trap column (Zorbax 300SB-C18, 0.3 × 5 mm; Agilent Technologies, Wilmington, DE, USA) at a flow rate of 15 μL/min in HPLC buffer A. The peptides were eluted by a linear gradient of HPLC buffer B (100% acetonitrile/0.1% formic acid) at a flow rate of 0.18 μL/min, and separated on an analytical column (nanoACQUITY UPLC C18 1.7 μm, 0.15 x 10 mm, Waters, Milford, MA, USA) coupled with in-line dilution at a flow rate of 0.1 μL/min HPLC buffer C (0.1% formic acid) for refocusing peptides. Eluted peptides were analyzed with a two-dimensional linear ion trap mass spectrometer LTQ-Orbitrap, which was controlled by Xcalibur 2.2 software (Thermo Fisher, San Jose, CA, USA). Intact peptides were detected in the full-scan MS, performed in the Orbitrap over a range of 400 to 2,000 Da and a resolution of 60,000 at m/z 400. Internal calibration was performed using the ion signal of (Si (CH3)2O)6H+ at m/z 536.165365 as a lock mass. Accurate m/z values were first entered as input into the inclusion list, and MS/MS analysis was performed on the LTQ–Orbitrap MS with a 10-ppm tolerance on the parent mass in to verify that the given peptides can be detected. Twenty MS/MS scan events (20 HCD) of 20 target precursor ions with most abundancy were followed by one preview MS scan. The m/z values selected for MS/MS were dynamically excluded for 15 seconds with a relative mass window of 15 ppm. The electrospray voltage was set to 2 kV, and the temperature of the capillary was set to 200°C. MS and MS/MS automatic gain control were set to 1,000 ms (full scan), 300 ms (HCD) or 3×106 ions (full scan) and 3×104 ions (HCD) for maximum accumulated time or ions, respectively.

Processing of LC-MS/MS data

The signals of the peptides were obtained by analyzing the RAW files with Maxquant 2.0.3.1 software. The intensity of the signal of the precursor was used as signals. The RAW files were converted into .mgf files. Based on mass, charge and retention time the precursor ions were selected initially by manual annotation and literature reports. This was then automated with a custom written python script, which used additionally to mass, charge, retention time and a scoring system for the fragments of the precursor ion to determine, if the precursor has a glycan change. The scoring system was based on the GlyxtoolMS software. The fucosylation, galactosylation and sialylation was estimated by normalizing the through the sum of the signal of all IgG1 N-297 glycopeptides as done in prior studies (7,15).

Statistical analysis

Statistical analysis was performed with R software using the dplyr package. Mann-Whitney-U test was used to compare between 2 samples. Kruskal-Wallis test to compare between multiple groups. P values<0.05 were considered as statistical significant.

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.06.16.23291455;](https://doi.org/10.1101/2023.06.16.23291455) this version posted June 20, 2023. The copyright holder for this preprint

Funding statement

This project was funded by the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (grant number: EMRPD1N0071)

Competing interests

The authors declare no competing interests.

References

- 1. Sayegh MH, Merhi A, Naal H, Saleh S. Global vaccination strategy to eradicate COVID-19: Beyond science. J Glob Health. 2021;11:1–5.
- 2. Kung YA, Huang SY, Huang CG, Liu KT, Huang PN, Yu KY, et al. Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines. Microbes Infect. 2023;25(1–2):105044.
- 3. Rossi MA, Cena T, Binala J, Alessi D, Scotti L, Faggiano F. Evaluation of the risk of SARS-CoV-2 infection and hospitalization in vaccinated and previously infected subjects based on real world data. Sci Rep. 2023;13(1):1–8.
- 4. Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. 2022;28(5):1072–82.
- 5. Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: Antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46–61.
- 6. Nimmerjahn F, Ravetch J V. Four keys to unlock igg. J Exp Med. 2021;218(3):2–4.
- 7. Larsen MD, de Graaf EL, Sonneveld ME, Plomp HR, Nouta J, Hoepel W, et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science (80-). 2021;371(6532):1–21.
- 8. Hoepel W, Chen HJ, Geyer CE, Allahverdiyeva S, Manz XD, de Taeye SW, et al. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci Transl Med. 2021;13(596).
- 9. Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2021;22(1):67–73.
- 10. Hsieh S-M, Liu W-D, Huang Y-S, Lin Y-J, Hsieh E-F, Lian W-C, et al. Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS- CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose- escalation study. EClinicalMedicine. 2021;
- 11. Farkash I, Feferman T, Cohen-Saban N, Avraham Y, Morgenstern D, Mayuni G, et al. Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. Cell Rep. 2021;37(11).

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.06.16.23291455;](https://doi.org/10.1101/2023.06.16.23291455) this version posted June 20, 2023. The copyright holder for this preprint

- 12. Buhre JS, Pongracz T, Künsting I, Lixenfeld AS, Wang W, Nouta J, et al. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing longterm IgG4 responses compared to an adenovirus-based vaccine. 2023;(January):1–18.
- 13. Irrgang P, Gerling J, Kocher K, Lapuente D, Steininger P, Wytopil M, et al. Class switch towards noninflammatory IgG isotypes after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol [Internet]. 2022;4(December)
- 14. Gregorek H, Madaliński K, Woynarowski M, Mikolajewicz J, Syczewska MX, Socha J. The IgG subclass profile of anti-HBs response in vaccinated children and children seroconverted after natural infection. Vaccine. 2000;18(13):1210–7.
- 15. Coillie J Van, Pongracz T, Rahmöller J, Chen H, Geyer E, Vught LA Van. The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees. EBioMedicine. 2023;87(December 2022):1–19.
- 16. Oosterhoff JJ, Larsen MD, van der Schoot CE, Vidarsson G. Afucosylated IgG responses in humans structural clues to the regulation of humoral immunity. Trends Immunol. 2022;43(10):800–14.
- 17. Kowarz E, Krutzke L, Külp M, Streb P, Larghero P, Reis J, et al. Vaccine-Induced Covid-19 Mimicry Syndrome. Elife. 2022;11:1–24.
- 18. Watanabe Y, Mendonça L, Allen ER, Howe A, Lee M, Allen JD, et al. Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. ACS Cent Sci. 2021;7(4):594–602.
- 19. Yonker LM, Swank Z, Bartsch YC, Burns MD, Kane A, Boribong BP, et al. Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis. Circulation. 2023;1–10.
- 20. Irvine EB, Alter G. Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. Glycobiology. 2021;30(4):241–53.
- 21. Shao P-L, Tu H-C, Gong Y-N, Hsu L, Yeo H, Kuo H, et al. Emergence and Persistent Dominance of SARS-CoV-2 Omicron BA.2.3.7 Variant, Taiwan. Emerg Infect Dis. 2023;29(4):792–6.

22. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and metaanalysis. PLoS One. 2021;16(6 June):1–21.

Figure 1: The NT titer estimated by anti-S IgG ELISA for each vaccine, for each dose. AZ: Astrazeneca. ** p<0.01

Figure 2: anti-S IgG subclass signal as fold change to the mean of 10 pre-vaccination anti-S IgG subclass signal for each vaccine and dose (**A-D**) and the change for each subclass and dose for each individual (**E-H**), AZ: Astrazeneca *p<0.05, ** p<0.01

Figure 3: anti-S IgG1 N-297 glycosylation as proportion of all n-297 for each vaccine and dose (**A-D**) and the change for each dose for each individual (**E-H**), AZ: Astrazeneca *p<0.05, ** p<0.01

